160 related articles for article (PubMed ID: 34860970)
1. Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.
Mohammad H; Borja-Hart N
J Pharm Technol; 2018 Aug; 34(4):144-148. PubMed ID: 34860970
[No Abstract] [Full Text] [Related]
2. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
Yang T; Zhou Y; Cui Y
Expert Opin Drug Saf; 2023 Nov; ():1-6. PubMed ID: 38009230
[TBL] [Abstract][Full Text] [Related]
3. A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use.
Shen J; Yang J; Zhao B
Diabetes Ther; 2019 Jun; 10(3):1043-1050. PubMed ID: 30953300
[TBL] [Abstract][Full Text] [Related]
4. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
[TBL] [Abstract][Full Text] [Related]
5. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
6. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
7. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
McGill JB; Subramanian S
Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440
[TBL] [Abstract][Full Text] [Related]
8. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
[TBL] [Abstract][Full Text] [Related]
9. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
10. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials.
Bhanushali KB; Asnani HK; Nair A; Ganatra S; Dani SS
Curr Probl Cardiol; 2024 May; 49(9):102664. PubMed ID: 38789017
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review.
Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J
Perm J; 2021 May; 25():. PubMed ID: 33970086
[TBL] [Abstract][Full Text] [Related]
13. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
Engelhardt K; Ferguson M; Rosselli JL
Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.
D'Elia JA; Segal AR; Bayliss GP; Weinrauch LA
Int J Nephrol Renovasc Dis; 2017; 10():153-158. PubMed ID: 28670136
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
[TBL] [Abstract][Full Text] [Related]
17. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
Suzuki M; Hiramatsu M; Fukazawa M; Matsumoto M; Honda K; Suzuki Y; Kawabe Y
Diabetes Obes Metab; 2014 Jul; 16(7):622-7. PubMed ID: 24400675
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
John M; Gopinath D; Jagesh R
Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
Vivian EM
Drugs Context; 2014; 3():212264. PubMed ID: 25598831
[TBL] [Abstract][Full Text] [Related]
20. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
